Top Markets
Coin of the day
Gilead Sciences, Inc. Gilead Sciences, Inc.

Gilead Sciences, Inc.

GILD
Clasificación en acciones #100
Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations... Gilead Sciences, Inc. is a global biopharmaceutical enterprise, with operations spanning the United States, Europe, and numerous international markets. Its core mission involves discovering, developing, and commercializing innovative medications to address critical health needs. The company's extensive product portfolio encompasses treatments for a variety of severe conditions. For HIV/AIDS, it supplies key therapies such as Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/Eviplera, Stribild, and Atripla. In response to the 2019 coronavirus pandemic, Gilead provides Veklury, an injectable drug for intravenous administration. Its offerings for liver diseases include Epclusa, Harvoni, Vosevi, Vemlidy, and Viread. Furthermore, Gilead assists patients battling hematological disorders, various cancers, and those undergoing cell therapy, through products like Yescarta, Tecartus, Trodelvy, and Zydelig. Other specialized medicines include Letairis, an oral drug for pulmonary arterial hypertension; Ranexa, also an oral medication, for chronic angina; and AmBisome, a liposomal formulation designed to combat serious invasive fungal infections. Gilead Sciences, Inc. actively engages in collaboration agreements with a diverse range of partners to advance its therapeutic pipeline. These include Arcus Biosciences, Inc., Pionyr Immunotherapeutics Inc., Tizona Therapeutics, Inc., Tango Therapeutics, Inc., Jounce Therapeutics, Inc., Galapagos NV, Janssen Sciences Ireland Unlimited Company, Japan Tobacco, Inc., Gadeta B.V., Bristol-Myers Squibb Company, Dragonfly Therapeutics, Inc., and Merck & Co, Inc. The company was founded in 1987 and its corporate headquarters are situated in Foster City, California.
Precio por acción
$150.78
Última sincronización: 2026-09-18
Capitalización bursátil
$187.20B
Cambio (1 día)
-0.08%
Cambio (1 año)
32.15%
País
US
Comercio Gilead Sciences, Inc. (GILD)

Categoría

Ganancias de Gilead Sciences, Inc. (GILD)
Ganancias en Jun 2026 TTM: $-1.96B
Secondo gli ultimi rapporti finanziari di Gilead Sciences, Inc., gli utili attuali della società sono $-1.96B. Nel 2024, la società ha registrato un utile di $690.00M, una disminución en comparación con agli utili del 2023, che erano di $6.86B. Gli utili mostrati in questa pagina sono quelli prima degli interessi e delle imposte, ovvero EBIT.
Historial de ganancias de Gilead Sciences, Inc. desde 2000 hasta 2026
Ganancias al final de cada año
Año Ganancias Cambiar
2026 (TTM) $-1.96B -119.96%
2025 $9.80B 1,319.71%
2024 $690.00M -89.94%
2023 $6.86B 17.97%
2022 $5.81B -29.77%
2021 $8.28B 395.99%
2020 $1.67B -67.66%
2019 $5.16B -33.84%
2018 $7.80B -42.35%
2017 $13.53B -20.87%
2016 $17.10B -21.06%
2015 $21.66B 45.79%
2014 $14.86B 253.04%
2013 $4.21B 16.50%
2012 $3.61B -1.07%
2011 $3.65B -6.71%
2010 $3.91B 11.75%
2009 $3.50B 31.03%
2008 $2.67B 17.72%
2007 $2.27B -455.74%
2006 $-638.21M -154.93%
2005 $1.16B 76.99%
2004 $656.42M -491.82%
2003 $-167.53M -328.26%
2002 $73.40M 27.76%
2001 $57.45M -237.08%
2000 $-41.91M 0.00%
Ganancias de empresas similares o competidoras
Empresa Ganancias Diferencia de ganancias País
$33.59B -1,818.38%
US
$25.20B -1,388.80%
US
$8.70B -544.96%
US
$21.39B -1,194.03%
CH
$5.95B -404.25%
US